Array comparative genomic hybridization (aCGH) is a microarray-based technique that utilizes discrete segments of DNA as immobilized targets for the identification of genome-wide chromosomal copy number changes. aCGH provides a high resolution, highly efficient means to detect, quantify and map regions of abnormal copy number ( gains and losses), by comparing the relative efficiency with which fluorescently-labeled test and reference DNA hybridize across the genome. aCGH has been used successfully for the submicroscopic analysis of autism, mental health disorders, cancer and constitutional chromosomal abnormalities.
Empire Genomics provides full service aCGH analysis for both BAC (ACCUArray Platform) and oligonucleotide (Agilent CGH platform) array based karyotyping. Upon receipt of the DNA or tissue samples, Empire will first check the sample quality using our proprietary QC procedures. If the sample passes our QC screening, aCGH will be performed on the sample. We will then provide all of the raw and processed data, complete with complimentary aCGHViewer software for interactive web-based viewing of the aCGH profile.
Sample turnaround times of less than one week (about 3-4 business days) makes the full service aCGH analysis attractive for all users. |
|
|
Empire Genomics manufactures high quality human BAC arrayed slides for array Comparative Genomic Hybridization (aCGH). aCGH utilizes discrete segments of DNA as immobilized targets to assess relative DNA copy number changes between two different fluorescently labeled DNA samples.
|
|
Read more...
|
|
|
Agilent’s microarray-based comparative genomic hybridization (aCGH) technology is a powerful solution to your research in cancer and developmental disorders. Choose from a wide product offering of whole genome and zoom-in 60-mer oligo CGH microarrays for human, mouse, and rat.
|
|
Read more...
|
|
|
|
|
|
Products and Services 
